Jump to content

5-MeO-MET: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
No edit summary
Citation bot (talk | contribs)
Bots
5,021,818 edits
Add: doi-access, page, s2cid, isbn. Removed parameters. | Use this bot. Report bugs. | Suggested by Neko-chan | #UCB_webform 6/19
 
(11 intermediate revisions by 9 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{drugbox
{{drugbox
| drug_name = 5-MeO-MET
| drug_name = 5-MeO-MET
| image = 5-MeO-MET_structure.png
| image = 5-MeO-MET.svg
| legal_UK =
| legal_UK =
| legal_DE =
| legal_DE =
| C = 14 | H = 20 | N = 2 | O = 1
| C = 14 | H = 20 | N = 2 | O = 1
| IUPAC_name = N-Ethyl-2-(5-methoxy-1H-indol-3-yl)-N-methylethan-1-amine
| IUPAC_name = N-Ethyl-2-(5-methoxy-1H-indol-3-yl)-N-methylethan-1-amine
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 16977-53-0
| CAS_number = 16977-53-0
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2CNT3HAM6G
| ChemSpiderID = 5051184
| ChemSpiderID = 5051184
| PubChem = 6619012
| PubChem = 6619012
Line 14: Line 18:
}}
}}


'''5-MeO-MET''' ('''5-Methoxy-N-methyl-N-ethyltryptamine''') is a relatively rare [[designer drug]] from the [[substituted tryptamine]] family, related to compounds such as [[N-Methyl-N-ethyltryptamine]] and [[5-MeO-DMT]].<ref>Schifano F, Orsolini L, Papanti D, Corkery J. NPS: Medical Consequences Associated with Their Intake. ''Curr Top Behav Neurosci''. 2017;32:351-380. {{doi|10.1007/7854_2016_15}} {{pmid|27272067}}</ref><ref>Palma-Conesa AJ, Ventura M, Galindo L, Fonseca F, Grifell M, Quintana P, Fornís I, Gil C, Farré M, Torrens M. Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis. ''Journal of Psychoactive Drugs'' 2017; 49(4): 297-305. {{doi|10.1080/02791072.2017.1320732}}</ref><ref>Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busardò FP, Huestis MA. Toxicology and Analysis of Psychoactive Tryptamines. ''International Journal of Molecular Sciences''. 2020; 21(23):9279. {{doi|10.3390/ijms21239279}}</ref> It was first synthesised in the 1960s and was studied to a limited extent,<ref>Gessner PK, Godse DD, Krull AH, McMullan JM. Structure-activity relationships among 5-methoxy-N:N-dimethyltryptamine, 4-hydroxy-N:N-dimethyltryptamine (psilocin) and other substituted tryptamines. ''Life Sci''., 1 Mar 1968, 7(5): 267–277. {{doi|10.1016/0024-3205(68)90200-2}}</ref><ref>Glennon RA, Gessner PK. Serotonin receptor binding affinities of tryptamine analogues. ''J. Med. Chem''., 1 Jan 1979, 22 (4), pp 428–432. {{doi|10.1021/jm00190a014}}</ref> but was first identified on the illicit market in June 2012 in Sweden.<ref>[https://www.emcdda.europa.eu/system/files/publications/734/EMCDDA-Europol_2012_Annual_Report_final_439477.pdf EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA (New drugs in Europe, 2012]</ref> It was made illegal in Norway in 2013,<ref>[https://lovdata.no/dokument/LTI/forskrift/2013-12-16-1557 Forskrift om endring i forskrift om narkotika]</ref> and is controlled under analogue provisions in numerous other jurisdictions.
'''5-MeO-MET''' ('''5-Methoxy-N-methyl-N-ethyltryptamine''') is a relatively rare [[designer drug]] from the [[substituted tryptamine]] family, related to compounds such as [[N-methyl-N-ethyltryptamine]] and [[5-MeO-DMT]].<ref name="pmid27272067">{{cite journal | vauthors = Schifano F, Orsolini L, Papanti D, Corkery J | title = NPS: Medical Consequences Associated with Their Intake | journal = Current Topics in Behavioral Neurosciences | volume = 32 | issue = | pages = 351–380 | date = 2017 | pmid = 27272067 | doi = 10.1007/7854_2016_15 | isbn = 978-3-319-52442-9 | doi-access = free }}</ref><ref name="pmid28569652">{{cite journal | vauthors = Palma-Conesa ÁJ, Ventura M, Galindo L, Fonseca F, Grifell M, Quintana P, Fornís I, Gil C, Farré M, Torrens M | title = Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis | journal = Journal of Psychoactive Drugs | volume = 49 | issue = 4 | pages = 297–305 | date = 2017 | pmid = 28569652 | doi = 10.1080/02791072.2017.1320732 | s2cid = 45394561 }}</ref><ref name="pmid33291798">{{cite journal | vauthors = Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busardò FP, Huestis MA | title = Toxicology and Analysis of Psychoactive Tryptamines | journal = International Journal of Molecular Sciences | volume = 21 | issue = 23 | date = December 2020 | page = 9279 | pmid = 33291798 | pmc = 7730282 | doi = 10.3390/ijms21239279 | doi-access = free }}</ref> It was first synthesised in the 1960s and was studied to a limited extent,<ref name="pmid5641719">{{cite journal | vauthors = Gessner PK, Godse DD, Krull AH, McMullan JM | title = Structure-activity relationships among 5-methoxy-n:n-dimethyltryptamine, 4-hydroxy-n:n-dimethyltryptamine (psilocin) and other substituted tryptamines | journal = Life Sciences | volume = 7 | issue = 5 | pages = 267–77 | date = March 1968 | pmid = 5641719 | doi = 10.1016/0024-3205(68)90200-2 }}</ref><ref name="pmid430481">{{cite journal | vauthors = Glennon RA, Gessner PK | title = Serotonin receptor binding affinities of tryptamine analogues | journal = Journal of Medicinal Chemistry | volume = 22 | issue = 4 | pages = 428–32 | date = April 1979 | pmid = 430481 | doi = 10.1021/jm00190a014 }}</ref> but was first identified on the illicit market in June 2012 in Sweden.<ref>{{cite web | url = https://www.emcdda.europa.eu/system/files/publications/734/EMCDDA-Europol_2012_Annual_Report_final_439477.pdf | title = EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA | work = New drugs in Europe, 2012 }}</ref> It was made illegal in Norway in 2013,<ref>{{cite web | url = https://lovdata.no/dokument/LTI/forskrift/2013-12-16-1557 | title = Forskrift om endring i forskrift om narkotika | trans-title = Regulations amending the regulations on drugs | language = Norwegian | work = Lovdata }}</ref> and is controlled under analogue provisions in numerous other jurisdictions.


== See also ==
== See also ==
* [[4-HO-MET]]
* [[4-HO-MET]]
* [[5-HO-DiPT]]
* [[5-EtO-DMT]]
* [[5-EtO-DMT]]
* [[5-Fluoro-MET]]
* [[5-MeO-EPT]]
* [[5-MeO-EPT]]
* [[5-MeO-MALT]]
* [[5-MeO-MALT]]
* [[5-MeO-MiPT]]
* [[5-MeO-MiPT]]
* [[7F-5-MeO-MET]]




== References ==
== References ==
Line 32: Line 37:


[[Category:Tryptamines]]
[[Category:Tryptamines]]
[[Category:Methoxy compounds]]
[[Category:Substances discovered in the 1960s]]




{{Pharm-stub}}
{{nervous-system-drug-stub}}

Latest revision as of 15:15, 30 November 2023

5-MeO-MET
Identifiers
  • N-Ethyl-2-(5-methoxy-1H-indol-3-yl)-N-methylethan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H20N2O
Molar mass232.327 g·mol−1
3D model (JSmol)
  • CCN(CCc1c[nH]c2c1cc(OC)cc2)C
  • InChI=1S/C14H20N2O/c1-4-16(2)8-7-11-10-15-14-6-5-12(17-3)9-13(11)14/h5-6,9-10,15H,4,7-8H2,1-3H3
  • Key:AVECDEWGCOLCPZ-UHFFFAOYSA-N

5-MeO-MET (5-Methoxy-N-methyl-N-ethyltryptamine) is a relatively rare designer drug from the substituted tryptamine family, related to compounds such as N-methyl-N-ethyltryptamine and 5-MeO-DMT.[1][2][3] It was first synthesised in the 1960s and was studied to a limited extent,[4][5] but was first identified on the illicit market in June 2012 in Sweden.[6] It was made illegal in Norway in 2013,[7] and is controlled under analogue provisions in numerous other jurisdictions.

See also[edit]

References[edit]

  1. ^ Schifano F, Orsolini L, Papanti D, Corkery J (2017). "NPS: Medical Consequences Associated with Their Intake". Current Topics in Behavioral Neurosciences. 32: 351–380. doi:10.1007/7854_2016_15. ISBN 978-3-319-52442-9. PMID 27272067.
  2. ^ Palma-Conesa ÁJ, Ventura M, Galindo L, Fonseca F, Grifell M, Quintana P, Fornís I, Gil C, Farré M, Torrens M (2017). "Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis". Journal of Psychoactive Drugs. 49 (4): 297–305. doi:10.1080/02791072.2017.1320732. PMID 28569652. S2CID 45394561.
  3. ^ Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busardò FP, Huestis MA (December 2020). "Toxicology and Analysis of Psychoactive Tryptamines". International Journal of Molecular Sciences. 21 (23): 9279. doi:10.3390/ijms21239279. PMC 7730282. PMID 33291798.
  4. ^ Gessner PK, Godse DD, Krull AH, McMullan JM (March 1968). "Structure-activity relationships among 5-methoxy-n:n-dimethyltryptamine, 4-hydroxy-n:n-dimethyltryptamine (psilocin) and other substituted tryptamines". Life Sciences. 7 (5): 267–77. doi:10.1016/0024-3205(68)90200-2. PMID 5641719.
  5. ^ Glennon RA, Gessner PK (April 1979). "Serotonin receptor binding affinities of tryptamine analogues". Journal of Medicinal Chemistry. 22 (4): 428–32. doi:10.1021/jm00190a014. PMID 430481.
  6. ^ "EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA" (PDF). New drugs in Europe, 2012.
  7. ^ "Forskrift om endring i forskrift om narkotika" [Regulations amending the regulations on drugs]. Lovdata (in Norwegian).


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=5-MeO-MET&oldid=1187644837"